# Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Source: https://onco.cc/trials/nct03478488/  
OnCo record `nct03478488` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Envafolimab, Gemcitabine and Oxaliplatin in biliary tract cancer, run by 3D Medicines (Sichuan) Co., Ltd., active and no longer recruiting.

## Summary

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC is a phase 3 interventional study registered as NCT03478488 by 3D Medicines (Sichuan) Co., Ltd., with 480 participants enrolled, started 2018-04-16 and due to reach its primary completion in 2024-09-10. Interventions recorded: KN035 plus Gemcitabine & oxaliplatin and Gemcitabine & oxaliplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03478488
- Phase: 3
- Setting: Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study
- Sponsor: 3D Medicines (Sichuan) Co., Ltd.
- Enrolled: 480

## Sources

- ClinicalTrials.gov NCT03478488: https://clinicaltrials.gov/study/NCT03478488

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [Envafolimab](https://onco.cc/drugs/envafolimab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)

---
JSON: https://onco.cc/api/v1/entities/nct03478488.json